biotech / news / / Rappler
Danish drug maker Novo Nordisk has fallen behind Eli Lilly in the weight-loss drug market.
Novo Nordisk is partnering with OpenAI to integrate AI across drug discovery and operations.
KEY POINTS
- Pilot AI programs will start soon, with full integration targeted by the end of 2026.
- OpenAI will help train Novo's workforce to increase AI literacy and productivity, not replace jobs.
- Novo aims to use AI to reduce future hiring needs by boosting employee efficiency.
COMPANIES
Summarized by Newsio from Rappler. How we summarize →